Arcturus Therapeutics: Business Model, SWOT Analysis, and Competitors 2026

Arcturus Therapeutics Holdings Inc. stands as a leading company in Healthcare. Generating $82.03 million in annual revenue (growing -68.4% year-over-year) and carrying a market capitalization of $206.00 million, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, Arcturus Therapeutics Holdings Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Arcturus Therapeutics Holdings Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Arcturus Therapeutics Holdings Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Arcturus Therapeutics Holdings Inc.'s position in the Biotechnology market today.

What You Will Learn

1. How Arcturus Therapeutics Holdings Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Arcturus Therapeutics Holdings Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Arcturus Therapeutics Holdings Inc.'s main competitors are and how the company compares on key financial metrics
4. Arcturus Therapeutics Holdings Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Arcturus Therapeutics Holdings Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $82.03 million annual revenue (TTM), +-68.4% YoY
• Market Cap: $206.00 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin -36.8%, operating margin -435.1%, net margin -80.2%
• Free Cash Flow: $9.18 million
• Return on Equity: -28.9% — reflects current investment phase
• Employees: See latest annual report

Who Owns Arcturus Therapeutics Holdings Inc.?

Arcturus Therapeutics Holdings Inc. is publicly traded on the NGM under the ticker symbol ARCT. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Arcturus Therapeutics Holdings Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Arcturus Therapeutics Holdings Inc. has approximately 0.03 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $7.25 per share as of early 2026.

Arcturus Therapeutics Holdings Inc.'s Mission Statement

Arcturus Therapeutics Holdings Inc.'s strategic mission is aligned with its core business activities in the Biotechnology sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Arcturus Therapeutics Holdings Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Arcturus Therapeutics Holdings Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Arcturus Therapeutics Holdings Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Arcturus Therapeutics Holdings Inc. Make Money?

As of 2026, Arcturus Therapeutics Holdings Inc. generates $82.03 million in annual revenue (growing -68.4% year-over-year), with a -36.8% gross margin and -435.1% operating margin. Market capitalization stands at $206.00 million. Here is how the company generates its revenue:

Arcturus generates revenue through direct sales of therapeutic products, licensing agreements, collaborations, and grants.

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review Arcturus Therapeutics Holdings Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

Arcturus Therapeutics Holdings Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how Arcturus Therapeutics Holdings Inc. creates, delivers, and captures value.

Key Partners: Arcturus Therapeutics Holdings Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Biotechnology sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Arcturus Therapeutics Holdings Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Arcturus Therapeutics Holdings Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (N/A employees), proprietary technology, and financial resources ($230.91M in cash).

Value Propositions: Arcturus Therapeutics Holdings Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Biotechnology market.

Customer Relationships: Arcturus Therapeutics Holdings Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Arcturus Therapeutics Holdings Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Arcturus Therapeutics Holdings Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Arcturus Therapeutics Holdings Inc.'s major costs include cost of goods sold (136.8% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 535.1% of revenue.

Revenue Streams: Arcturus Therapeutics Holdings Inc. generates revenue through its core product and service offerings.

Arcturus Therapeutics Holdings Inc. Competitors

Arcturus Therapeutics Holdings Inc. competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Biotechnology segment of the Healthcare sector.

Arcturus Therapeutics Holdings Inc. SWOT Analysis

A SWOT analysis examines Arcturus Therapeutics Holdings Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Established Market Position: Arcturus Therapeutics Holdings Inc. holds an established position in the Biotechnology sector, with a track record of serving customers and generating value across its core business activities.
• Industry Expertise: The company's deep expertise in Biotechnology — developed over years of operation — provides meaningful barriers to entry and customer relationship advantages that newer competitors must overcome.

Weaknesses

• Revenue Decline: Year-over-year revenue declined 68.4%, raising questions about demand for Arcturus Therapeutics Holdings Inc.'s core offerings and requiring management to articulate a credible recovery path.

Opportunities

• Total Addressable Market: Arcturus Therapeutics Holdings Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Arcturus Therapeutics Holdings Inc.'s products and services.
• Strategic Acquisitions: With $230.91M in cash and strong free cash flow generation, Arcturus Therapeutics Holdings Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Arcturus Therapeutics Holdings Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Arcturus Therapeutics Holdings Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Arcturus Therapeutics Holdings Inc. enters 2026 as a leading company in Healthcare, backed by $82.03 million in annual revenue and a -80.2% net profit margin. The company's -36.8% gross margins and $9.18 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Arcturus Therapeutics Holdings Inc.'s core markets.

For investors and analysts, Arcturus Therapeutics Holdings Inc. represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Arcturus Therapeutics, SEC EDGAR – Arcturus Therapeutics Filings, and Arcturus Therapeutics's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What is Arcturus Therapeutics Holdings Inc.?

Arcturus Therapeutics Holdings Inc. generated $82.03 million in annual revenue with a -80.2% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult Arcturus Therapeutics Holdings Inc.'s investor relations page.

2. What is the focus of Arcturus's research and development?

Arcturus Therapeutics Holdings Inc. generated $82.03 million in annual revenue with a -80.2% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult Arcturus Therapeutics Holdings Inc.'s investor relations page.

3. What are the strengths of Arcturus Therapeutics?

Arcturus Therapeutics Holdings Inc.'s core strengths include: Arcturus Therapeutics Holdings Inc. holds an established position in the Biotechnology sector, with a track record of serving customers and generating value across its core business activities. The company's deep expertise in Biotechnology — developed over years of operation — provides meaningful barriers to entry and customer relationship advantages that newer competitors must overcome. These advantages contribute to the company's durable competitive position in the Biotechnology sector.

4. Who are the main competitors of Arcturus Therapeutics?

Arcturus Therapeutics Holdings Inc. competes in the Biotechnology segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Biotechnology center on product differentiation, pricing strategy, and distribution scale.

5. What opportunities does Arcturus Therapeutics have?

Arcturus Therapeutics Holdings Inc.'s key growth opportunities include: Arcturus Therapeutics Holdings Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Arcturu With $230.91M in cash and strong free cash flow generation, Arcturus Therapeutics Holdings Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geog

6. What are the potential threats facing Arcturus Therapeutics?

Arcturus Therapeutics Holdings Inc. faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Arcturus Therapeutics Holdings Inc.'s revenue is not fully insulated from macroeconomic cycl Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Arcturus Therapeuti Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.

7. How does Arcturus generate revenue?

Arcturus Therapeutics Holdings Inc. generates $82.03 million in annual revenue (TTM) with a -36.8% gross margin, growing -68.4% year-over-year. The company's revenue model is described in detail in the business model section above.